## Alan C Bird

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2267285/publications.pdf

Version: 2024-02-01

		81900	ç	95266
75	7,571	39		68
papers	citations	h-index		g-index
77	77	77		5600
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Role of retinal pigment epithelium in age-related macular disease: a systematic review. British Journal of Ophthalmology, 2021, 105, 1469-1474.	3.9	14
2	The X-linked retinopathies: Physiological insights, pathogenic mechanisms, phenotypic features and novel therapies. Progress in Retinal and Eye Research, 2021, 82, 100898.	15.5	65
3	Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2. British Journal of Ophthalmology, 2021, 105, 573-576.	3.9	10
4	Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits—a pilot study. Eye, 2021, , .	2.1	3
5	Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging and age-related macular degeneration. Scientific Reports, 2021, 11, 10349.	3.3	5
6	Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 394-409.	5.2	153
7	Reanalysis of Association of Pro50Leu Substitution in Guanylate Cyclase Activating Protein-1 With Dominant Retinal Dystrophy. JAMA Ophthalmology, 2020, 138, 200.	2.5	5
8	Exploratory Study on Visual Acuity and Patient-Perceived Visual Function in Patients with Subretinal Drusenoid Deposits. Journal of Clinical Medicine, 2020, 9, 2832.	2.4	3
9	Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19. American Journal of Ophthalmology, 2020, 216, A5-A6.	3.3	27
10	A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in Healthy Ageing and Age-Related Macular Degeneration. Journal of Clinical Medicine, 2020, 9, 1001.	2.4	14
11	Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. Acta Ophthalmologica, 2019, 97, e998-e1005.	1.1	22
12	Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2. Ophthalmology, 2019, 126, 540-549.	5.2	110
13	Peripheral Retinal Imaging Biomarkers for Alzheimer's Disease: A Pilot Study. Ophthalmic Research, 2018, 59, 182-192.	1.9	64
14	SCOTOMA CHARACTERISTICS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S14-S19.	1.7	13
15	CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S8-S13.	1.7	51
16	CORRELATION OF STRUCTURAL AND FUNCTIONAL OUTCOME MEASURES IN A PHASE ONE TRIAL OF CILIARY NEUROTROPHIC FACTOR IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2018, 38, S27-S32.	1.7	23
17	LONGITUDINAL CORRELATION OF ELLIPSOID ZONE LOSS AND FUNCTIONAL LOSS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S20-S26.	1.7	58
18	ABNORMAL RETINAL REFLECTIVITY TO SHORT-WAVELENGTH LIGHT IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2018, 38, S79-S88.	1.7	26

#	Article	IF	Citations
19	Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT. Ophthalmology, 2018, 125, 537-548.	5.2	485
20	CHARACTERISTICS OF PIGMENTED LESIONS IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2018, 38, S43-S50.	1.7	28
21	Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration. Ophthalmology, 2017, 124, 464-478.	5.2	164
22	Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Progress in Retinal and Eye Research, 2016, 53, 70-106.	15.5	159
23	Perspectives on reticular pseudodrusen in age-related macular degeneration. Survey of Ophthalmology, 2016, 61, 521-537.	4.0	72
24	Unusual Retinal Vascular Proliferation in von Hippel-Lindau Disease. JAMA Ophthalmology, 2016, 134, 1073.	2.5	1
25	Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial deposit formation in the aging eye. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1565-1570.	7.1	101
26	Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1ÂSafety Trial. American Journal of Ophthalmology, 2015, 159, 659-666.e1.	3.3	72
27	MULTIMODAL IMAGING IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2015, 35, 742-749.	1.7	35
28	A Population-Based Ultra-Widefield DigitalÂlmage Grading Study for Age-RelatedÂMacular Degeneration–Like Lesions at the Peripheral Retina. Ophthalmology, 2015, 122, 1340-1347.	5.2	44
29	Intermediate uveitis associated with familial Mediterranean fever. Clinical and Experimental Rheumatology, 2015, 33, S170.	0.8	2
30	Geographic Atrophy. JAMA Ophthalmology, 2014, 132, 338.	2.5	144
31	Pathogenetic Mechanisms in Age-Related Macular Degeneration. , 2013, , 1145-1149.		1
32	Macular telangiectasia type 2. Progress in Retinal and Eye Research, 2013, 34, 49-77.	15.5	311
33	Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2) MacTel Project Report No. 3. Ophthalmic Epidemiology, 2013, 20, 109-113.	1.7	50
34	Macular Pigment Parameters in Patients with Macular Telangiectasia (MacTel) and Normal Subjects: Implications of a Novel Analysis., 2012, 53, 6568.		42
35	The IS/OS Junction Layer in the Natural History of Type 2 Idiopathic Macular Telangiectasia. , 2012, 53, 7889.		70
36	"En face―OCT Imaging of the IS/OS Junction Line in Type 2 Idiopathic Macular Telangiectasia. , 2012, 53, 6145.		98

#	Article	IF	CITATIONS
37	Electroretinogram measures in a septuagenarian population. Documenta Ophthalmologica, 2011, 123, 75-81.	2.2	22
38	The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD). Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 209-214.	1.9	23
39	Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiology, 2010, 17, 66-73.	1.7	132
40	Therapeutic targets in age-related macular disease. Journal of Clinical Investigation, 2010, 120, 3033-3041.	8.2	154
41	What Should a Clinician Know to be Prepared for the Advent of Treatment of Retinal Dystrophies?. Novartis Foundation Symposium, 2008, , 85-94.	1.1	3
42	Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16651-16656.	7.1	201
43	High concentration of zinc in sub-retinal pigment epithelial deposits. Experimental Eye Research, 2007, 84, 772-780.	2.6	117
44	Complement C3 Variant and the Risk of Age-Related Macular Degeneration. New England Journal of Medicine, 2007, 357, 553-561.	27.0	762
45	How to keep photoreceptors alive. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2033-2034.	7.1	4
46	Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1453-1460.	1.9	14
47	The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular Study. Acta Ophthalmologica, 2006, 84, 636-641.	0.3	33
48	Photopic and Scotopic Fine Matrix Mapping of Retinal Areas of Increased Fundus Autofluorescence in Patients with Age-Related Maculopathy., 2004, 45, 574.		141
49	What should a clinician know to be prepared for the advent of treatment of retinal dystrophies?. Novartis Foundation Symposium, 2004, 255, 85-90; discussion 90-4, 177-8.	1.1	1
50	The Prevalence of Age-Related Maculopathy in Iceland. JAMA Ophthalmology, 2003, 121, 379.	2.4	107
51	Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss11Commercial interests: None American Journal of Ophthalmology, 2002, 133, 341-349.	3.3	179
52	Retinal pigment epithelium translocation and central visual function in age related macular degeneration: preliminary results. International Ophthalmology, 2001, 23, 297-307.	1.4	24
53	Novel mutations of theRPGR gene in RP3 families. Human Mutation, 2000, 15, 386-386.	2.5	12
54	Novel frameshift mutations in the RP2 gene and polymorphic variants. Human Mutation, 2000, 15, 580-580.	2.5	22

#	Article	IF	CITATIONS
55	Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nature Genetics, 2000, 25, 462-466.	21.4	392
56	NRL S50T mutation and the importance of †founder effects†in inherited retinal dystrophies. European Journal of Human Genetics, 2000, 8, 783-787.	2.8	18
57	A mutation in NRL is associated with autosomal dominant retinitis pigmentosa. Nature Genetics, 1999, 21, 355-356.	21.4	205
58	A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nature Genetics, 1999, 22, 199-202.	21.4	453
59	Distribution of pigment epithelium autofluorescence in retinal disease state recorded in vivo and its change over time. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 1-9.	1.9	113
60	Refined genetic and physical positioning of the gene for Doyne honeycomb retinal dystrophy (DHRD). Human Genetics, 1999, 104, 77-82.	3.8	15
61	Treatment of pigment epithelial detachments due to ageâ€related macular degeneration with intraâ€ocular C <sub>3</sub> F <sub>8</sub> injection*. Australian and New Zealand Journal of Ophthalmology, 1998, 26, 311-317.	0.4	13
62	Localisation of a gene for dominant cone-rod dystrophy (CORD6) to chromosome 17p. Human Molecular Genetics, 1997, 6, 597-600.	2.9	50
63	Relationship between Melatonin Rhythms and Visual Loss in the Blind (sup) 1 (/sup). Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3763-3770.	3.6	227
64	Familial pars planitis and dominant optic atrophy. Ophthalmic Genetics, 1997, 18, 43-45.	1.2	7
65	Dominantly inherited drusen represent more than one disorder: A historical review. Eye, 1995, 9, 34-41.	2.1	67
66	Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. Human Mutation, 1994, 3, 409-410.	2.5	46
67	Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. Nature Genetics, 1993, 3, 213-218.	21.4	483
68	Correlation between Lipids Extracted from Bruch's Membrane and Age. Ophthalmology, 1993, 100, 47-51.	5.2	128
69	Correlation between Biochemical Composition and Fluorescein Binding of Deposits in Bruch's Membrane. Ophthalmology, 1992, 99, 1548-1553.	<b>5.</b> 2	165
70	Histopathology of Incipient Fundus Flavimaculatus. Ophthalmology, 1991, 98, 953-956.	5.2	80
71	Aging Changes in Bruch's Membrane. Ophthalmology, 1990, 97, 171-178.	5.2	279
72	Sorsby's Fundus Dystrophy. Ophthalmology, 1989, 96, 1763-1768.	5.2	97

## Alan C Bird

#	Article	IF	CITATIONS
73	Sorsby's Fundus Dystrophy. Ophthalmology, 1989, 96, 1769-1777.	<b>5.</b> 2	149
74	The Pathogenesis of Tears of the Retinal Pigment Epithelium. American Journal of Ophthalmology, 1988, 105, 285-290.	<b>3.</b> 3	87
75	The ABCA4 2588G>C Stargardt mutation: single origin and increasing frequency from South-West to North-East Europe. , 0, .		1